Explore the dynamic landscape of pharma deals, mergers, acquisitions, and partnerships. Stay informed about strategic collaborations, licensing agreements, and investments shaping the industry. Get insights into the business side of pharmaceuticals and discover the key players driving innovation and growth.

Alexion Gains Voyager's Preclinical Capsid in $1B Pfizer Handoff

Alexion Acquires Voyager’s Preclinical Capsid for Rare Neurological Disease After $1B Pfizer Transfer

Anika Sharma

Pfizer has transferred an AAV capsid designed for a rare neurological disease target to AstraZeneca’s rare disease subsidiary, Alexion, as ...

BMS Acquires Orum's ADC ORM-6151 for AML and MDS Treatment

BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment

Anika Sharma

Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...

AstraZeneca Invests in Cellectis for Therapy Push

AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture

Anika Sharma

AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...

Prelude Shifts Focus, Cuts Phase 1 Drugs in New Deal

Prelude Focuses on SMARCA in AbCellera Deal and Trims Its Portfolio by Dropping Two Phase 1 Candidates

Anika Sharma

Prelude Therapeutics is undergoing a strategic shift, significantly streamlining its clinical pipeline to focus on the promising potential of its ...

Moderna and CEPI team up for 100 Days Mission

Moderna partners with CEPI to speed up vaccine development for future pandemics

Anika Sharma

Moderna is teaming up with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute to the 100 Days Mission, an ...

United Therapeutics buys Miromatrix for $91M

United Therapeutics acquires Miromatrix for bioengineered organ research

Anika Sharma

United Therapeutics is set to enhance its arsenal of organ manufacturing technologies with the acquisition of Miromatrix Medical, a developer ...

Merck's $169M Investment in PARP1 inhibitors Challenges AstraZeneca & Gilead

Merck Invests $169M in Selective PARP1 Drug, Intensifying Competition with AstraZeneca and Gilead

Anika Sharma

Merck KGaA is making a strategic move in the field of PARP inhibitors, investing a substantial 160 million euros ($169 ...

Accenture Song buys ConcentricLife for $245M | Pharma News

Accenture Song acquires ConcentricLife for $245M to boost ad capabilities

Anika Sharma

Accenture, known for its relentless pursuit of acquisitions, has returned to the deal table once again. The global services company, ...

Elektrofi gets $20M from Lilly for drug deal

Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership

Anika Sharma

Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...

AxoSim, organoid, Vyant Bio, asset sales, neuroscience, Biotech

AxoSim acquires Vyant’s organoid tech for brain disorder research

Anika Sharma

AxoSim, a New Orleans-based drug discovery biotech, has successfully completed the acquisition of the neuroscience research assets from Vyant Bio’s ...

Roche Snaps Up Telavant and Its IBD Drug

Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy

Anika Sharma

Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...

Merck Ends Some ADC Development with Kelun

Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo

Anika Sharma

Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...

Merck-Daiichi $22B deal for cancer ADCs

Merck and Daiichi join forces to develop novel cancer drugs in $22B deal

Anika Sharma

In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...

PTC cashes in $1.5B from Evrysdi royalty deal

PTC sells royalty rights of SMA drug Evrysdi to Royalty Pharma for $1.5B

Anika Sharma

As part of its cost-cutting efforts and in response to potential challenges in the European market, PTC Therapeutics is taking ...

Avania buys two medtech CROs, grows globally

Avania acquires two medtech CROs, broadens its global services and expertise

Anika Sharma

Avania, a medtech-focused Contract Research Organization (CRO) headquartered in the Netherlands, has extended its industry expertise through the strategic acquisitions ...

Lilly buys Elahere, boosts ADC portfolio

Lilly acquires European biotech Elahere, expands its ADC network and pipeline

Anika Sharma

Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...

Basilea acquires antifungal from Eisai

Basilea buys clinical-stage antifungal from Eisai, advances its anti-infective strategy

Anika Sharma

Basilea Pharmaceutica is making a strategic move to bolster its anti-infective pipeline, this time with a $2 million investment in ...

Siemens and team up for TB screening

Siemens Healthineers and to deploy AI-powered chest X-ray screening for TB

Anika Sharma

Siemens Healthineers, in collaboration with and the Global Fund to Fight AIDS, Tuberculosis, and Malaria, is intensifying efforts to ...

SpliceBio and Spark join forces for eye gene therapy

SpliceBio and Roche’s Spark Therapeutics team up for eye disease gene therapy

Anika Sharma

SpliceBio Initiates $216 Million Collaboration with Roche’s Gene Therapy Unit to Pave the Way for Innovative Inherited Retinal Disease Treatment ...

Gilead and Assembly Bio ink antiviral deal

Gilead strikes $100 million deal with Assembly Bio for antiviral assets

Anika Sharma

Gilead Sciences is taking a unique approach to secure early access to Assembly Biosciences’ promising programs. Instead of an outright ...

Roche and Monte Rosa team up for molecular glue

Roche partners with Monte Rosa to develop molecular glue drugs for cancer

Anika Sharma

In a dynamic move, Roche has forged its second major agreement in the realm of molecular glue technology, this time ...

concentra rain oncology deal, rain oncology cancer drugs, concentra healthcare company, rain oncology financial troubles, concentra acquisition offer, rain oncology news, concentra news,

Concentra makes a bid to buy Rain Oncology, a struggling biotech with two cancer drugs

Anika Sharma

Concentra Biosciences, having weathered a failed acquisition of Atea Pharmaceuticals earlier this year, has now turned its attention to Rain ...

Novo Nordisk, chronic kidney disease, Kerendia, non-steroidal mineralocorticoid receptor antagonist, product acquisition, KBP Biosciences

Novo Nordisk acquires Corvidia Therapeutics for $1.3B to compete with Bayer’s Kerendia

Anika Sharma

Novo Nordisk, riding high on the success of its semaglutide sales, has taken a strategic leap by investing up to ...

sotio synaffix deal, sotio adc technology, synaffix adc platform, sotio lead drug halted, sotio news, synaffix news, adc tech licensing,

Sotio inks $740M deal with Synaffix for ADC technology after lead drug setback

Anika Sharma

In a strategic move following the recent setback in its IL-15 asset trials, Sotio Biotech has embarked on an ambitious ...

lonza antibody filling line, lonza switzerland jobs, lonza biotech collaboration, antibody drug conjugates, lonza visp expansion, lonza news, lonza antibody production,

Lonza to create over 100 jobs in Switzerland with new antibody filling line and expanded collaboration

Anika Sharma

In a series of recent strategic moves, Lonza, the prominent Swiss Contract Development and Manufacturing Organization (CDMO), is making headlines. ...

Eversana Intouch buys Healthware Group in biopharma deal

Eversana Intouch acquires Healthware Group to expand its biopharma services portfolio

Anika Sharma

Eversana Intouch, a prominent biopharma services company in the United States, is taking a significant step by acquiring its long-standing ...

Astria joins eczema race with Ichnos’ drug deal

Astria buys rights to Ichnos’ eczema drug for $15M, joining crowded field of Amgen and Sanofi

Anika Sharma

Ichnos Sciences has secured a buyer for its OX40 eczema program, with Astria Therapeutics entering the scene by paying an ...

Haemonetics buys OpSens for $253M, a maker of smart TAVR guidewires

Haemonetics buys OpSens for $253M, a maker of smart TAVR guidewires

Anika Sharma

Boston-based medical device manufacturer Haemonetics is continuing its focus on expanding its portfolio of interventional cardiology devices with a strategic ...

Kanvas Bio emerges from Federation’s demise with clinical-stage assets

Kanvas Bio emerges from Federation’s demise with clinical-stage assets

Anika Sharma

In a strategic move, Kanvas Biosciences has seized the opportunity to acquire key assets from Federation Bio, a biotech company, ...

BMS invests more in Cellares to boost cell therapy manufacturing

BMS invests more in Cellares to boost cell therapy manufacturing

Anika Sharma

Just six weeks following the initial announcement of a partnership between cell and gene therapy manufacturer Cellares and Bristol Myers ...

1235 Next